http://www.empr.com Latest articles from MPR MPR Home Concise prescription and over-the-counter drug information and news, including side effects, interactions, dosing, and contraindications. Over 3000 drugs written by pharmacists for medical professionals. Home Admin@haymarketmedia.com no Heavy consumption of soft drinks is linked to an increased risk of asthma and chronic obstructive pulmonary disease (COPD). http://www.empr.com/heavy-soda-drinking-tied-to-asthma-copd/article/227339/ Fri, 10 Feb 2012 19:00:00 GMT Heavy consumption of soft drinks is linked to an increased risk of asthma and chronic obstructive pulmonary disease (COPD). MPR Drivers under the influence of cannabis are twice as likely to be involved in motor vehicle collisions, particularly fatal collisions. http://www.empr.com/risk-of-collision-doubles-for-drivers-using-cannabis/article/227345/ Fri, 10 Feb 2012 19:00:00 GMT Drivers under the influence of cannabis are twice as likely to be involved in motor vehicle collisions, particularly fatal collisions. MPR Baby-led weaning though the use of finger foods, rather than continued spoon-feeding, promotes healthy food preferences in early childhood. http://www.empr.com/baby-led-weaning-linked-to-healthy-food-preferences/article/227333/ Fri, 10 Feb 2012 18:30:00 GMT Baby-led weaning though the use of finger foods, rather than continued spoon-feeding, promotes healthy food preferences in early childhood. MPR General health outcomes and central nervous system, cardiac, and auditory morbidity are not affected by fetal exposure to chemotherapy over the long term, although premature infants exposed to chemotherapy in utero experience impaired cognitive development. http://www.empr.com/no-long-term-impairment-from-prenatal-exposure-to-chemo/article/227327/ Fri, 10 Feb 2012 18:00:00 GMT General health outcomes and central nervous system, cardiac, and auditory morbidity are not affected by fetal exposure to chemotherapy over the long term, although premature infants exposed to chemotherapy in utero experience impaired cognitive development. MPR Robot-assisted laparoscopic pyeloplasty (RLP) is safe and efficacious for the repair of ureteropelvic junction obstruction (UPJO). http://www.empr.com/robotic-surgery-repairs-urinary-tract-obstruction/article/227321/ Fri, 10 Feb 2012 18:00:00 GMT Robot-assisted laparoscopic pyeloplasty (RLP) is safe and efficacious for the repair of ureteropelvic junction obstruction (UPJO). MPR New evidence-based clinical practice guidelines have been issued for the prophylaxis of venous thromboembolism (VTE) in nonsurgical patients. http://www.empr.com/guidelines-for-vte-prophylaxis-in-nonsurgical-patients-issued/article/227201/ Fri, 10 Feb 2012 15:00:00 GMT New evidence-based clinical practice guidelines have been issued for the prophylaxis of venous thromboembolism (VTE) in nonsurgical patients. MPR Insmed announced that it is proceeding with a Phase 2 clinical trial of Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease. http://www.empr.com/phase-2-study-update-of-arikace-for-non-tuberculous-mycobacteria-lung-disease/article/227264/ Fri, 10 Feb 2012 14:57:20 GMT Insmed announced that it is proceeding with a Phase 2 clinical trial of Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease. MPR Intracerebroventricular (ICV) infusion of opioids is safe and effective for the treatment of nonresponsive pain in terminally-ill patients in home settings. http://www.empr.com/intracerebroventricular-opioid-infusion-feasible-at-home/article/227219/ Fri, 10 Feb 2012 14:00:00 GMT Intracerebroventricular (ICV) infusion of opioids is safe and effective for the treatment of nonresponsive pain in terminally-ill patients in home settings. MPR Updated Warnings/Precautions: increased risk of asthma-related deaths and hospitalizations. Interactions: concomitant strong CYP3A4 inhibitors. http://www.empr.com/serevent-diskus/asthmacopd/drug/6718/ Fri, 10 Feb 2012 05:00:00 GMT Updated Warnings/Precautions: increased risk of asthma-related deaths and hospitalizations. Interactions: concomitant strong CYP3A4 inhibitors. MPR The FDA has notified healthcare professionals that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir; Merck) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors can potentially reduce the effectiveness of these medicines when they are used together. http://www.empr.com/safety-alert-drug-interactions-between-protease-inhibitors-for-hepatitis-c-and-hiv/article/227159/ Thu, 09 Feb 2012 20:09:25 GMT The FDA has notified healthcare professionals that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir; Merck) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors can potentially reduce the effectiveness of these medicines when they are used together. MPR Evidence suggests that transdermal testosterone patches may relieve symptoms of hypoactive sexual desire disorder (HSDD) in postmenopausal women. http://www.empr.com/testosterone-patches-improve-low-sexual-desire-disorder/article/227096/ Thu, 09 Feb 2012 17:00:00 GMT Evidence suggests that transdermal testosterone patches may relieve symptoms of hypoactive sexual desire disorder (HSDD) in postmenopausal women. MPR Mylan announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Doxycycline hyclate delayed-release tablets USP, 150mg. http://www.empr.com/mylan-receives-approval-for-first-generic-version-of-doryx/article/227063/ Thu, 09 Feb 2012 16:44:40 GMT Mylan announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Doxycycline hyclate delayed-release tablets USP, 150mg. MPR ConvaTec has launched Aquacel Ag Burn Dressing, a soft, absorbent, non-woven wound dressing for the management of partial thickness burns (PTBs) and donor sites. http://www.empr.com/aquacel-ag-burn-dressing-for-partial-thickness-burns/article/227060/ Thu, 09 Feb 2012 16:03:34 GMT ConvaTec has launched Aquacel Ag Burn Dressing, a soft, absorbent, non-woven wound dressing for the management of partial thickness burns (PTBs) and donor sites. MPR BioSante announced positive safety data from ongoing Phase 3 trials of LibiGel (testosterone) for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. http://www.empr.com/phase-3-study-update-of-libigel-for-female-sexual-dysfunction/article/227059/ Thu, 09 Feb 2012 15:43:34 GMT BioSante announced positive safety data from ongoing Phase 3 trials of LibiGel (testosterone) for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. MPR How Supplied: updated http://www.empr.com/epipen/anaphylaxis/drug/3530/ Thu, 09 Feb 2012 05:00:00 GMT How Supplied: updated MPR How Supplied: updated http://www.empr.com/epipen-jr/anaphylaxis/drug/3531/ Thu, 09 Feb 2012 05:00:00 GMT How Supplied: updated MPR Genzyme announced four-year follow-up data from its Phase 2 clinical trial of eliglustat tartrate for the treatment of Gaucher disease type 1. http://www.empr.com/phase-2-trial-update-of-eliglustat-for-the-treatment-of-gaucher-disease/article/226967/ Wed, 08 Feb 2012 20:28:23 GMT Genzyme announced four-year follow-up data from its Phase 2 clinical trial of eliglustat tartrate for the treatment of Gaucher disease type 1. MPR Forest Laboratories and Gedeon Richter Plc announced preliminary results from a Phase 3 trial of cariprazine (RGH-188) in patients with acute mania associated with bipolar I disorder. http://www.empr.com/phase-3-study-update-of-cariprazine-for-acute-mania-in-bipolar-i-disorder/article/226860/ Wed, 08 Feb 2012 15:52:38 GMT Forest Laboratories and Gedeon Richter Plc announced preliminary results from a Phase 3 trial of cariprazine (RGH-188) in patients with acute mania associated with bipolar I disorder. MPR Avanir Pharmaceuticals announced results of a Phase 3 randomized controlled trial of AVP-923 in the treatment of diabetic neuropathic pain. http://www.empr.com/phase-3-study-of-avp-923-for-diabetic-neuropathic-pain/article/226856/ Wed, 08 Feb 2012 15:40:46 GMT Avanir Pharmaceuticals announced results of a Phase 3 randomized controlled trial of AVP-923 in the treatment of diabetic neuropathic pain. MPR APP announced that it will launch Imipenem and Cilastatin for Injection and Meropenem for Injection, generic versions of Primaxin IV (Merck) and Merrem IV (AstraZeneca), respectively. http://www.empr.com/app-to-launch-imipenem-and-cilastatin-for-injection-and-meropenem-for-injection/article/226850/ Wed, 08 Feb 2012 14:27:46 GMT APP announced that it will launch Imipenem and Cilastatin for Injection and Meropenem for Injection, generic versions of Primaxin IV (Merck) and Merrem IV (AstraZeneca), respectively. MPR Monograph added. http://www.empr.com/optimark/diagnostic-agents/drug/9938/ Wed, 08 Feb 2012 05:00:00 GMT Monograph added. MPR Monograph added. http://www.empr.com/optiray-240/diagnostic-agents/drug/9939/ Tue, 07 Feb 2012 05:00:00 GMT Monograph added. MPR Oxycodone HCl 5mg, 7.5mg; tabs. http://www.empr.com/oxecta/drugproduct/204/ Mon, 06 Feb 2012 15:30:00 GMT Oxycodone HCl 5mg, 7.5mg; tabs. MPR Mylan announced that it has acquired the abbreviated new drug application (ANDA) for Clindamycin Phosphate / Benzoyl Peroxide gel, the generic version of Valeant's BenzaClin, and a license to manufacture and market Fluorouracil 5%, the generic version of Valeant's Efudex Cream. http://www.empr.com/mylan-acquires-two-dermatological-products-from-valeant/article/227141/ Mon, 06 Feb 2012 15:00:00 GMT Mylan announced that it has acquired the abbreviated new drug application (ANDA) for Clindamycin Phosphate / Benzoyl Peroxide gel, the generic version of Valeant's BenzaClin, and a license to manufacture and market Fluorouracil 5%, the generic version of Valeant's Efudex Cream. MPR Acorda Therapeutics announced that it has partnered with Watson Pharma to launch Tizanidine HCl capsules, an authorized generic version of its Zanaflex capsules. http://www.empr.com/acorda-and-watson-to-launch-generic-zanaflex-capsules/article/227140/ Mon, 06 Feb 2012 14:00:00 GMT Acorda Therapeutics announced that it has partnered with Watson Pharma to launch Tizanidine HCl capsules, an authorized generic version of its Zanaflex capsules. MPR Mylan announced that the FDA has granted tentative approval for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium tablets. http://www.empr.com/mylan-receives-tentative-fda-approval-for-generic-lipitor/article/227143/ Thu, 02 Feb 2012 14:00:00 GMT Mylan announced that the FDA has granted tentative approval for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium tablets. MPR